British drug 70% decreased the growth of aggressive tumors

Bertoneri in combination with chemotherapy affects the DNA of cancer cells, not allowing her to recover.


Specialists from the Institute of cancer research UK are looking for new ways to fight cancer. British scientists have focused on the ability of cancer cells to restore DNA. In the course of studies has identified the ATR protein, which is responsible for the repair of cells, which were exposed to the drug personaltab. Scientists did not expect so much positive effect, because the British drug in combination with chemotherapy 70% decreased the growth of aggressive tumors. Experts believe that made a breakthrough in the treatment of severe forms of cancer, because patients with such diagnoses have experienced a new drug.

The success of the operation personeria is that chemotherapy also affects the DNA of tumors makes them more sensitive to the ingredients of the new drug. To date, the side effects of the drug are mild and do not go to any comparison with the benefit from personaltime. Scientists are going to continue to create tools that act on the DNA of cancer tumors.

Kartashov Timur



Tumors, an experimental compound blocks its growth: revolutionary discovery in Padua

Tumors, a very important and revolutionary discovery by the Veneto Institute of Molecular Medicine (VIMM) and the University of Padua. A new experimental compound blocks the tumor growth. The results obtained demonstrate, in particular, that angiogenesis, the process of formation of new blood vessels essential for the repair and regeneration of tissues, but also for the growth of tumors and the development of metastases, depends on the Opa1 protein present in the mitochondria.


#correlati article figure .player_clicker :: after {         color: #fff;         background-color: rgba (0,0,0,0.6);         border-radius: 50%;         display: block;         text-align: center;         font-size: 16px;         line-height: 40px;         width: 40px;         position: absolute;         top: 50%;         left: 50%;         margin: -20px 0 0 -21px;     }     #correlati article figure .player_foto_clicker :: after {         color: #fff;         background-color: rgba (0,0,0,0.6);         border-radius: 50%;         display: block;         text-align: center;         font-size: 20px;         line-height: 40px;         width: 40px;         position: absolute;         top: 50%;         left: 50%;         margin: -20px 0 0 -21px;     }


Mother’s Day, AIRC and Amazon together to bring azalea to Italian homes and support research

Coronavirus, dogs sniff Covid-19 faster than tests: studies in England and training centers in Iran

Using an innovative anti-Opa1 drug researchers managed to block the tumor growth. There are several drugs in clinical use that block the angiogenesis process and remove nutrients from the tumor preventing it from growing, but often these drugs fail to prevent the progression of the disease. Despite the proven efficacy of some drugs, they are unable to block tumor expansion. “We discovered – explains Luca Scorrano, Scientific director of Vimm – that mitochondria quickly change their shape when angiogenesis is activated, an indication of their participation in the process of formation of new blood vessels. A bioinformatic analysis indicated that the mitochondrial protein Opa1 could be implicated in these sudden changes in shape during angiogenesis. Belgian researcher Stéphanie Herkenne has verified that the activation of Opa1 is indeed essential for angiogenesis: if Opa1 is not activated, angiogenesis cannot proceed. The genetic inactivation of the Opa1 gene in blood vessel cells blocks the growth and metastasis of tumors in laboratory experiments, two processes that depend precisely on angiogenesis.Using an experimental compound that blocks Opa1, the researchers noted a reduction between the 70-80% of the growth of experimental tumors.

Coronavirus does not stop bone marrow transplants at the “Santa Maria Goretti” hospital



UNUSUAL: Doctors remove tumor with hair and teeth in Siberia

The life of the medical Surgeons are not easy, because they have in their hands the life of a person who is undergoing an operation on which the future of their days will depend.

As in daily life, medicine also has highs and lows, and rarely has cases of caliber unusual that challenge the parameters set by modern medicine and challenge medical with facts that seem to have no explanation.

Such is the case of some medical from the Russian city of Tyumen, in Siberiawho extracted a tumor It contained hairs and teeth, as reported by the Regional Health Department of the aforementioned place.

Doctors remove tumor with hair and teeth in Siberia

“A patient diagnosed with an ovarian cyst entered the clinic. During a laparoscopic laser ovarian cystectomy, the gynecologist discovered that, in addition to the fatty tissue, the cyst contained a bundle of hair and four teeth, “states the report of the institution.

However, despite this unusual fact in the medical field, the operation was carried out without any problem, and the day after the surgery the woman was discharged from the hospital. hospital successfully.

UNUSUAL: Doctors remove tumor with hair and teeth in Siberia.

The doctors instructed the woman to take extreme care during the following week after her operation so that she would heal properly and thus continue with her daily life as she did before having the stranger. tumor that was withdrawn.

The health department explained that such benign tumors are caused due to the poor development of embryonic cells, so they can contain almost all the tissues of the body, however unusual they may seem.

UNUSUAL: Doctors remove tumor with hair and teeth in Siberia.

It may interest you: UNUSUAL: Man drives robot remotely with his sphincter!

Hair, nails, cartilage, bones, teeth, organs and parts of the body are some of the elements that can develop in a tumor, because in general, tumors occur when cells divide and multiply excessively in the body.


Atomic Veterans of America – NBC Connecticut

The enemy Hank Bolden
faced did not come from a distant front line.

It came from the skies.

It’s a battle that’s still going on 65 years later. Bolden, who is now 82 years old, is an atomic veteran – one of hundreds of thousands of American service members used in human testing by the United States government during post-WWII nuclear tests and sworn to a secret life.

“They wanted to see how the living soldiers would resist the exposure
to radiation, ”recalls Bolden. “Before using live soldiers they were using
mannequins. But you don’t get real results using mannequins as you would
live bodies. “


While accompanying a friend to a New Haven recruiting station in 1953, Bolden was invited to join the army. At just 16 years old then and already out of high school, he admits that he “pulled down” his birth certificate to move to the age of 18, joining the approximately 200,000 underage soldiers who would have served during the Second World War and the eras of the Korean War.

After basic training in
Fort Dix was assigned to work as a tank mechanic in Texas before moving to Texas
California and becoming a surface-to-air missile mechanic.

Despite an executive order issued in July
26, 1948, by President Harry S. Truman to desegregate the armed forces, the last one
the all black units of the army were not abolished until 1954. And in 1955, Bolden
he says, racist attitudes persist even after the units have been racially integrated.

“The residual thoughts of people were firm
linger, “he says.” My outfit was 800 people strong. Thirteen of us were
black. Ten were from the South, who were more tolerant of treatment
they got racially. But the three of us from the North couldn’t tolerate it,
so I have had many fights over this. So I was the guy they wanted
get rid of.”

It would not be the only race
discrimination Bolden would witness as a soldier.


In 1955, the seventeen year old
he was suddenly ordered to the Nevada desert without explanation.

“They don’t tell you what you’re going to face,” he said. “Nobody
they knew what they were going to face. ”

What he would eventually face was a classified operation known as Operation Teapot at the Nevada Test Site. In a series of 14 bomb throws, or “hits”, military officials tried to test the effects of nuclear bombs on structures and strategies, animals and people.

All races of military personnel
participated in the Teapot operation. But upon arrival in Nevada, Bolden was
astounded to accomplish all the other soldiers in his new specially selected unit
for a mysterious assignment they were also black.

“There was this myth about black people
be able to resist, tolerate certain things more than any other race “, he
He says. “So it was a test on that too.”


One morning in February, Bolden
the unit was ordered in a desert trench. Unbeknownst to them, it was excavated
the expected route of the fallout, only 2.8 miles away from what it would have become
ground zero for the launch of an atomic bomb.

Even though a countdown sounded on the speakers, Bolden says, the soldiers still had no idea what they were about to face. Without protective gear in addition to the normal fabrics and helmets, they waited and looked.

“They tell you to cover your eyes”
he says.

On February 18, 1955, Shot Wasp, the first nuclear test of Operation Teapot, detonated a Mark 6 nuclear bomb dropped by a B-36 exactly at noon. A monstrous cloud of mushrooms filled the sky, reaching 21,500 feet in height.

“With radiation, when you put your arms over your eyes or hands, you actually see the bones, you see the bones in your body from the exposure. You can see your skeleton. “

After the relapse the warning came.

“You swore not to speak
“said Bolden. The soldiers were threatened with imprisonment and fines for violation
The oath.

For 60 years, Bolden didn’t tell anyone. No this
family, not his wife, not his children. Not even her doctors when she spies on her
tumors have started to show. He developed bladder and posterior subcapsular cancer
cataract and in 1990 multiple myeloma was diagnosed.

“They actually gave me three and a half years
four years to live, ”recalls Bolden.
So in 1995 I should have been a statistic. “

But in 1995, Bolden was in remission. He is a citizen
the secret was coming to light.


Government figures estimate between 400,000 and 550,000 US military personnel who participated in a series of nuclear tests between 1946 and 1992. According to the Department of Defense’s Defense Threat Reduction Agency, this includes post occupation forces -Second World War of Hiroshima and Nagasaki, prisoners of war in Japan at the end of the Second World War, participants in the atmospheric nuclear tests in Nevada and the Pacific from 1945 to 1962 and participants in the underground nuclear tests in Nevada from 1951 to 1992.

Many of these “atomic veterans” have succumbed before their own
the stories have become public, their bodies are full of tumors. In
1990, the veil of secrecy began to lift.

After setting up the Advisory Committee on Human Radiation Experiments to investigate 10-year experiments, President Clinton made a formal apology to American atomic veterans on October 3, 1995. By order of the president, Congress would repeal the nuclear radiation agreement law. and secrecy, allowing atomic veterans to talk about their experiences without fear of fines or treason charges. And financial compensation has been opened to all qualified atomic veterans.

“Those who led the government when these decisions were made are no longer here to take responsibility for what they have done. They are not here to apologize to survivors, family members or their communities whose lives have been overshadowed by shadow of these choices So today, on behalf of another generation of American leaders and another generation of American citizens, the United States of America offers sincere apologies to those of our citizens who have undergone these experiments. the government is wrong, we have a moral responsibility to admit it, “said President Bill Clinton on October 3, 1995

But the television address has been obscured. The same happened
day when OJ Simpson’s verdict was issued in a live classroom feed, taking
on televisions and news cycles across America.

As a result, many skilled veterans had no idea of ​​the ban
the secrecy had been lifted, nor that they could claim benefits. Bolden no
find out until he researched the Internet, he says, in 2015.

“I was once so angry and so aggravating with the government that I thought I would be murdered to keep me from talking,” he says.

When Bolden attempted to apply for subsidies, he found that the burden of proof was placed on his fellow atomic veterans. The government would give compensation from the date a complaint was filed, but not retroactively, and only if the veteran could prove that he had participated in the tests – which proved to be an almost impossible task after millions of military documents were destroyed in a 1973 fire against the National Staff Registration Center. As many as 18 million documents were burned, including 80% of all army personnel discharged between 1912 and 1960.

“They hoped for it
would have died sooner or would have been one of those guys who surrendered ”
says Anthony Bolden, Hank’s son. “No thanks. Hank doesn’t have it.”

After paying her
own pocket for a polygraph lie detector pouch, Hank eventually claimed
approved, setting a precedent for other atomic veterans whose records were

Photo: Hidden story: the atomic veterans of America

Hit a high note

“The love of music has
I’ve always been there. “

After his honorable discharge
from the army, Bolden went to work as an engineer before deciding to pursue a
career as a jazz musician who works while his family grows. Tell the story
while cradling the tenor saxophone that has been at his side since 1967. The “Rolls
Royce “of tools, he says.

The brand is Selmer. IS
in a strange coincidence, the model is a 6 sign. It is the same name as the shot
Wasp atomic bomb design.

But this is where the
the similarities end. The bomb was his nightmare. Music, his dream and his
outlet to work through the trauma of what lived in Nevada

“It’s like the blood inside
my veins. It takes away all my other thoughts, “he says

Bolden is finally
he receives compensation from the government and is now using it to help make his dream come true.
He returned to school, studying jazz performances at Hartt University of Hartford

“They are like the relic
here with all these kids, you know, “he chuckles.

Professor Javon Jackson
says that the 82-year-old is leaving a unique mark on the prestigious program.

“He has a lot of emotion,” says Jackson. “He is a very bluesy, very full of feeling, a natural player. His life, wisdom and the things he has acquired allow him to play the way it sounds.”


The vast majority of
Today, the American atomic veterans of the atmospheric test era are gone. About
400,000 veterans were present during these tests, according to the veterans
Administration. Survivors’ numbers vary, from around 10,000 to 80,000
still alive.

Bolden believes he is one of only two surviving African American atomic veterans who are recognized and receive compensation from the government. He is on a mission to reach as many survivors as possible and help them request the long-awaited recognition and compensation.

And he’s sharing his story, he says, to make sure the plight of American atomic veterans is no longer ignored.

“When people like me pass by, this won’t be part of the story unless someone makes sure it’s kept alive.”


CAR-T light-controlled cells selectively destroy skin tumors in mice




Bioengineers of the University of California, San Diego have developed a control system that could make therapy with CAR-T cells Be safer and more powerful when treating cancer. When programming these cells to turn on when exposed to blue light, The researchers controlled the cells to destroy skin tumors in mice without damaging healthy tissue, as published in the journal «Science Advanced».

In tests in mice, administration of engineered CAR-T cells and stimulation of skin tumor spots with blue LED light They reduced the size of the tumor between eight and nine times. The results were observed in nine out of ten mice tested. CAR-T cells designed by themselves they were not able to inhibit tumor growth.

Chimeric antigen receptor (CAR) T-cell therapy is a promising new approach to treating cancer. Is about collect a patient’s T cells and genetically design them to express special receptors on their surface that can recognize an antigen in the selected cancer cells. The manipulated T cells are infused back into the patient to find and attack the cells that have the target antigen on their surface.

The manipulated T cells are infused back into the patient to find and attack the cells that have the target antigen on their surface.

While this approach has worked good for some types of blood cancer and lymphoma, until now It has not worked well against solid tumors. One reason is because many specific cancer antigens they are also expressed in healthy cells

«It is very difficult to identify an ideal antigen for solid tumors with high specificity, so that the cells CAR-T only target these diseased tumor sites without attacking normal organs and tissues – explains Peter Yingxiao Wang, professor of Irwin School of Engineering and Joan Jacobs in the UC San Diego-. Therefore, there is a great need to design CAR-T cells that can be controlled with high precision in space and time ».

This approach could be used to treat solid tumors near the surface of the skin. For future studies, Wang is looking to collaborate with doctors to evaluate the approach in melanoma patients

To create such cells, Wang and his team they installed a power switch that would allow them to activate cells at a specific site in the body. The switch uses two engineering proteins located inside the cell that bind when exposed to pulses of blue light of a second. Once bound, the proteins trigger the expression of the receptor directed to the antigen.

Since light cannot penetrate deep into the body, Wang imagines that this approach could be used to treat tumors solids close to the skin’s surface. For future studies, Wang is looking to collaborate with doctors to evaluate the approach in patients with melanoma.